These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 2106400

  • 1. Adverse hemodynamic effects of antiarrhythmic drugs in congestive heart failure.
    Hammermeister KE.
    Circulation; 1990 Mar; 81(3):1151-3. PubMed ID: 2106400
    [No Abstract] [Full Text] [Related]

  • 2. Comparative hemodynamic effects of procainamide, tocainide, and encainide in severe chronic heart failure.
    Gottlieb SS, Kukin ML, Medina N, Yushak M, Packer M.
    Circulation; 1990 Mar; 81(3):860-4. PubMed ID: 2106401
    [Abstract] [Full Text] [Related]

  • 3. Congestive heart failure induced by six of the newer antiarrhythmic drugs.
    Ravid S, Podrid PJ, Lampert S, Lown B.
    J Am Coll Cardiol; 1989 Nov 01; 14(5):1326-30. PubMed ID: 2509529
    [Abstract] [Full Text] [Related]

  • 4. [New anti-arrhythmia drugs].
    Vidal Garate J, Romero-Ayala LC, Cárdenas Loaeza M.
    Arch Inst Cardiol Mex; 1983 Nov 01; 53(2):159-78. PubMed ID: 6411015
    [Abstract] [Full Text] [Related]

  • 5. New antiarrhythmic drugs: tocainide, mexiletine, flecainide, encainide, and amiodarone.
    Kreeger RW, Hammill SC.
    Mayo Clin Proc; 1987 Nov 01; 62(11):1033-50. PubMed ID: 3118116
    [Abstract] [Full Text] [Related]

  • 6. Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents.
    Woosley RL, Echt DS, Roden DM.
    Am J Cardiol; 1986 Jan 31; 57(3):25B-33B. PubMed ID: 3080860
    [Abstract] [Full Text] [Related]

  • 7. Antiarrhythmic drug therapy (Part 2). Benefits and hazards.
    Podrid PJ.
    Chest; 1985 Oct 31; 88(4):618-24. PubMed ID: 3930162
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The use of antiarrhythmic agents in heart failure: implications of CAST.
    Gottlieb SS.
    Am Heart J; 1989 Nov 31; 118(5 Pt 1):1074-7. PubMed ID: 2510486
    [No Abstract] [Full Text] [Related]

  • 13. A review of the uses and limitations of tocainide--a class IB antiarrhythmic agent.
    Morganroth J, Nestico PF, Horowitz LN.
    Am Heart J; 1985 Oct 31; 110(4):856-63. PubMed ID: 3931446
    [Abstract] [Full Text] [Related]

  • 14. Antiarrhythmic drug therapy. Recent advances and current status.
    Somberg J.
    Cardiology; 1985 Oct 31; 72(5-6):329-48. PubMed ID: 2866841
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cardiac electrophysiology of four new antiarrhythmic drugs--encainide, flecainide, lorcainide and tocainide.
    Camm AJ.
    Eur Heart J; 1984 Sep 31; 5 Suppl B():75-9. PubMed ID: 6437820
    [No Abstract] [Full Text] [Related]

  • 19. Chemistry, pharmacology, antiarrhythmic efficacy and adverse effects of tocainide hydrochloride, an orally active structural analog of lidocaine.
    Alpert JS, Haffajee CI, Young MD.
    Pharmacotherapy; 1983 Sep 31; 3(6):316-23. PubMed ID: 6419205
    [Abstract] [Full Text] [Related]

  • 20. Electrocardiographic and hemodynamic effects of tocainide (W-36095) in man.
    Swedberg K, Pehrson J, Rydén L.
    Eur J Clin Pharmacol; 1978 Nov 09; 14(1):15-9. PubMed ID: 729602
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.